Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne Tam

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Cell|November 1, 2011
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphomaElisa Oricchio, Gouri Nanjangud, Andrew L Wolfe, et al.
Cancers|June 21, 2020
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical DiscoveriesDanilo Fiore, Luca Vincenzo Cappelli, Paul Zumbo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 2, 2021
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology GroupOlga K Weinberg, Karen M Chisholm, Chi Young Ok, et al.
Haematologica|July 25, 2024
Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphomaJohanne M Holst, Martin B Pedersen, Marie B Enemark, et al.
Cancer Discovery|August 20, 2013
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphomaThomas Clozel, ShaoNing Yang, Rebecca L Elstrom, et al.
Cell|October 4, 2016
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T CellsMichael Boice, Darin Salloum, Frederic Mourcin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specifiedSa A Wang, Wayne Tam, Albert G Tsai, et al.
Blood|August 18, 2022
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilitiesLuca Vincenzo Cappelli, Danilo Fiore, Jude M Phillip, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Life Science Alliance|December 28, 2020
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progressionAndré F Rendeiro, Joseph Casano, Charles Kyriakos Vorkas, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Cell|November 1, 2011
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphomaElisa Oricchio, Gouri Nanjangud, Andrew L Wolfe, et al.
Cancers|June 21, 2020
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical DiscoveriesDanilo Fiore, Luca Vincenzo Cappelli, Paul Zumbo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 2, 2021
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology GroupOlga K Weinberg, Karen M Chisholm, Chi Young Ok, et al.
Haematologica|July 25, 2024
Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphomaJohanne M Holst, Martin B Pedersen, Marie B Enemark, et al.
Cancer Discovery|August 20, 2013
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphomaThomas Clozel, ShaoNing Yang, Rebecca L Elstrom, et al.
Cell|October 4, 2016
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T CellsMichael Boice, Darin Salloum, Frederic Mourcin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specifiedSa A Wang, Wayne Tam, Albert G Tsai, et al.
Blood|August 18, 2022
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilitiesLuca Vincenzo Cappelli, Danilo Fiore, Jude M Phillip, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Life Science Alliance|December 28, 2020
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progressionAndré F Rendeiro, Joseph Casano, Charles Kyriakos Vorkas, et al.
Pageof 14